Clinical Trial Update: Study of Nalbuphine HCl ER Tablets in Patients With Prurigo Nodularis [Phase 2, Phase 3]

View source ↗

Summary

A completed Phase 2/Phase 3 clinical trial evaluated nalbuphine HCl extended-release tablets for prurigo nodularis, with results posted in August 2020.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prurigo Nodularis

Drugs mentioned

• Nalbuphine HCl ER Tablets (nalbuphine hydrochloride extended-release)

Snippet

Sponsor: Trevi Therapeutics | Conditions: Prurigo Nodularis, Nodularis Prurigo | Phase 2, Phase 3 | Status: COMPLETED | Results posted: 2020-08-21